Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onilcamotide in prostate cancer biochemical failure
NCT04114825Phase 2Active, not recruiting
- Sponsor
- RhoVac AB
- Start
- Nov 2019
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, Peptide-based Cancer Vaccines
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing RV001V with Placebo (2 arms). Primary endpoint: Time to PSA progression up to 3 years. Started Nov 2019; status: active, not recruiting.
02
Drugs
onilcamotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04114825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114825.